EU Approves Biogen's Tofersen as First Treatment for SOD1 ALS - NeurologyLive

Retrieved on: 2024-06-07 15:49:24

Tags for this article:

Metalloproteins

Oxidoreductases

Biogen

Spinal muscular atrophy

SOD1

Placebo-controlled study

Click the tags to see associated articles and topics

EU Approves Biogen's Tofersen as First Treatment for SOD1 ALS - NeurologyLive. View article details on hiswai:

Excerpt

Following presented phase 1 clinical trial findings at AAN 2024, bemdaneprocel receives regenerative medicine advanced therapy designation by the FDA ...

Article found on: www.neurologylive.com

View Original Article